Scinai Immunotherapeutics Ltd.
SCNI · XNASCIK 1611747fmd_1TJ0QA8Z5EXKX7TPC76WCNDX0VManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 23 periods
| Line item | FY2017 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 1 | 1 |
| Trading and principal transactions revenue | – | – | – | – | 26 | 26 | 26 |
| Cost of revenue | – | – | – | – | – | 1 | 4 |
| Gross profit | – | – | – | – | – | (1) | (3) |
| Research and development | 5 | 16 | 3 | 6 | 5 | 6 | 2 |
| Selling, general and administrative | 1 | – | 8 | 5 | 5 | 3 | 3 |
| Total operating expenses | – | – | 11 | 11 | 10 | 8 | 5 |
| Operating income | – | – | (11) | (11) | (10) | (9) | (8) |
| Interest expense | 3 | 5 | 0 | 0 | 0 | – | – |
| Interest and investment income | – | – | – | – | 0 | – | – |
| Other non-operating income (expense) | – | – | 3 | 5 | 3 | (1) | (1) |
| Net income from continuing operations | – | – | 3 | 8 | – | – | – |
| Net income | (10) | (1) | (8) | (6) | (7) | 5 | (8) |
| Net income to common shareholders | – | – | 8 | 6 | 7 | – | – |